Cytokinetics (CYTK): Reset Creates Room for Re-Engagement: Thoughts into 3Q

CYTK has lagged the broader tape since ESC in a challenging macro environment (~-20% vs NBI ~-8% since Aug. 27, 2026) and shares are now trading around the level before we saw positive results from the phase 3 ACACIA-HCM trial in non-obstructive HCM (nHCM) in May. As we approach 3Q26 results next month, our top inbound recently has been what will get the stock to work again. To some extent, we see Edgewise's expected near-term disclosure around their phase 3 plan for HCM as helpful in lifting what is perceived to be a competitive overhang for some, though we still think that Myqorzo and EDG-7500, if successful, could both coexist successfully in the marketplace over the long-term. That said, we think what is more critical for investors to re-engage in the name and for shares to regain momentum is for the market to see a clear path to value creation over the coming months as we move towards 2027 and our J.P. Morgan Healthcare Conference driven by continued strong Myqorzo trends in obstr